ReviewTurkish journal of urology2021
Transperineal prostate biopsy: The modern gold standard to prostate cancer diagnosis.
Review in Turkish journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07011342 (Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.ESMO open · 2022Guideline
- Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures.Prostate cancer and prostatic diseases · 2026Review
- Transperineal (TP) Versus Transrectal (TR) Prostate Biopsy: Efficacy, Safety, and Systemic Challenges-A Narrative Review.Journal of clinical medicine · 2026Review
- Infection rates of trans-perineal versus trans-rectal prostate biopsy: A Middle Eastern tertiary center experience-Time for a change?Arab journal of urology · 2026Article
- Identification of prostate cancer by urinary DLX1/HOXC6 expression in Chinese population with prostate-specific antigen levels of 4-10 ng/mL.Scientific reports · 2025Article
- Comparative Analysis of Transperineal Cognitive Fusion, Systematic, and Combined Biopsies for Prostate Cancer Detection.Medicina (Kaunas, Lithuania) · 2025Article
- The carbon footprint of transperineal prostate biopsy.BJUI compass · 2025Article
- Review
- Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study.Iranian journal of pathology · 2024Article
- Potential Diagnostic Biomarker Detection for Prostate Cancer Using Untargeted and Targeted Metabolomic Profiling.Current issues in molecular biology · 2023Article
- Freehand transperineal prostate biopsy with a coaxial needle under local anesthesia: Experience from a single institution in Malaysia.Cancer pathogenesis and therapy · 2023Article
- Prostate cancer screening: Continued controversies and novel biomarker advancements.Current urology · 2022Article
- Recent Development of Drug Delivery Systems through Microfluidics: From Synthesis to Evaluation.Pharmaceutics · 2022Review
- Recent Advances in Systematic and Targeted Prostate Biopsies.Research and reports in urology · 2021Review
- The Design and Rationale of a Multicentre Randomised Controlled Trial Comparing Transperineal Percutaneous Laser Ablation With Transurethral Resection of the Prostate for Treating Benign Prostatic Hyperplasia.Frontiers in surgery · 2021Article
- Article
- Schema and cancer detection rates for transperineal prostate biopsy templates: a review.Therapeutic advances in urologyReview
- Hundred years of transperineal prostate biopsy.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients suspicious for prostate cancer, a prostate biopsy should be performed. Biopsies are possible either by the transrectal or transperineal routes. Compared with the transrectal prostate biopsy (TRPBx), transperineal prostate biopsy (TPPBx) offers a non-inferior cancer detection rate (CDR), especially in patients undergoing re-biopsy for persistently elevated PSA and in cases of active surveillance (AS), in which TPPBx seems to be superior. Moreover, the transperineal route achieves superior sampling of the anterior and apical regions, especially after previous multiple negative TRPBx. Infectious complications are nullified due to avoidance of needle passage through the rectal mucosa, and there is a highly significant evidence of reduced fever and sepsis rates when compared with TRPBx, with maintaining acceptable urinary retention rates. This is an important upcoming topic due to the increasing antibiotic resistance rates, thus reducing periinterventional hospitalization and health care costs. To date, TPPBx is perfectly feasible in the inpatient and out-patient settings and under local anesthesia, characterized by a moderate learning curve and a good reproducibility. By applying mpMRI as a diagnostic tool, clinically significant prostate cancer (csPCa) detection seems to be comparable to transrectal MRI-fusion biopsy (TR-MRIFBx). Finally, focal treatment of localized disease is currently performed exclusively through a TP approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.